LeadArtis news image

About the cover: Model of an asymmetric bispecific scFv-based N/C-trimerbody. The scFv-domains with the same specificity are colored in blue or green, and the trimerization region is colored in red. Visit Landes Bioscience issue online

Focused on developing cancer immune therapeutic bispecific antibodies 

LeadArtis is an early stage biotechnology company based in Madrid (Spain) that develops targeted drugs based on its proprietary Trimerbody® protein engineering platform. 


Trimerbody® is an alternative antibody format that employs specific collagen trimerization domains and optimized peptide connectors to provide advantages over conventional antibodies including simultaneous multiple targeting (up to six per molecule), reduced size, higher avidity for targets, and a variety of effector possibilities such as immune system modulation, receptor modulation, soluble factor neutralization, payload delivery etc. Our key therapeutic areas for pipeline development are oncology and inflammatory/autoimmunity.

Additionally, we offer our Trimerbody® platform to partners interested in developing targeted drugs benefiting from the Trimerbody® format which offers promising opportunities over competitors including pharmacokinetics adapted to the pathological context.

Latest News

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao

Leadartis will participate in BioSpain 2016 to be held...